We established Roquefort Therapeutics plc to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. The investment strategy of the Company is to provide Shareholders with an attractive total return achieved primarily through capital appreciation. The Directors believe that there are numerous investment opportunities within both private and public businesses in the medical biotech sector in the United Kingdom, Continental Europe and Australia.